Precipio Inc

precipiodx.com

What Do They Do?

Provides specialized cancer diagnostic testing to physicians, hospitals and laboratories, and develops diagnostic assay kits for clinical laboratories.

How Do They Make Money?

Patients and payers pay for diagnostic tests when Precipio delivers the report; research and biomarker customers pay as contracted results are delivered. Laboratories pay for diagnostic products when they are delivered.

revenue

Segment	Share	Revenue	How money arrives
Service revenue, net Sold outright	89% FY2022: 85%		Sold outright
Product revenue Sold outright	11%		Sold outright

Who Are Their Customers?

Physicians, hospitals and laboratories receive specialized cancer testing; clinical laboratories obtain proprietary assay kits through laboratory partners and commercial channels.

Do Revenues Turn Into Profits?

Not on paper. It lost $363K in FY2025, but brought in more cash than it spent: $374K of free cash flow.

Operating income, FY2025

−5% of revenue

▼ −71% (Loss) vs FY2024 (−$4.2M, −23%)

Net income, FY2025

−2% of revenue

▼ −92% (Loss) vs FY2024 (−$4.3M, −23%)

Free cash flow, FY2025

2% of revenue

▲ +73% vs FY2024 ($216K, 1%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +24%; vs $5.7M in Q2 FY2025
Net income: ▼ Now a loss; vs $74K in Q2 FY2025

Service revenue, net share of revenue vs 89.0% in Q2 FY2025

Growing. Revenue grew 2.7x in 4 years, from $8.8M in FY2021 to $24M in FY2025, about 28% a year.

Revenue over time

Service revenue, net Product revenue Other

$25M$12.5M$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with NeoGenomics, GenPath Diagnostics, Inform Diagnostics, LabCorp, Quest Diagnostics, Foundation Medicine, Guardant Health, Qiagen, BioRad, Ipsogen, Cepheid, Asuragen, Abbott, Entrogen, Life Technologies, Illumina, Roche, Natera, PerkinElmer, and Gibco

Comments